174 related articles for article (PubMed ID: 37463500)
1. Discovery of HDAC6, HDAC8, and 6/8 Inhibitors and Development of Cell-Based Drug Screening Models for the Treatment of TGF-β-Induced Idiopathic Pulmonary Fibrosis.
Yu WC; Yeh TY; Ye CH; Chong PCT; Ho YH; So DK; Yap KY; Peng GR; Shao CH; Jagtap AD; Chern JW; Lin CS; Lin SP; Lin SL; Yu SH; Yu CW
J Med Chem; 2023 Aug; 66(15):10528-10557. PubMed ID: 37463500
[TBL] [Abstract][Full Text] [Related]
2. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
Negmeldin AT; Knoff JR; Pflum MKH
Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
[TBL] [Abstract][Full Text] [Related]
3. Tubastatin ameliorates pulmonary fibrosis by targeting the TGFβ-PI3K-Akt pathway.
Saito S; Zhuang Y; Shan B; Danchuk S; Luo F; Korfei M; Guenther A; Lasky JA
PLoS One; 2017; 12(10):e0186615. PubMed ID: 29045477
[TBL] [Abstract][Full Text] [Related]
4. The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
Negmeldin AT; Pflum MKH
Bioorg Med Chem Lett; 2017 Aug; 27(15):3254-3258. PubMed ID: 28648461
[TBL] [Abstract][Full Text] [Related]
5. Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors.
Zhao C; Zang J; Ding Q; Inks ES; Xu W; Chou CJ; Zhang Y
Eur J Med Chem; 2018 Apr; 150():282-291. PubMed ID: 29533873
[TBL] [Abstract][Full Text] [Related]
6. Tubastatin A suppresses renal fibrosis via regulation of epigenetic histone modification and Smad3-dependent fibrotic genes.
Choi SY; Ryu Y; Kee HJ; Cho SN; Kim GR; Cho JY; Kim HS; Kim IK; Jeong MH
Vascul Pharmacol; 2015 Sep; 72():130-40. PubMed ID: 25921924
[TBL] [Abstract][Full Text] [Related]
7. Identification of a novel aminotetralin class of HDAC6 and HDAC8 selective inhibitors.
Tang G; Wong JC; Zhang W; Wang Z; Zhang N; Peng Z; Zhang Z; Rong Y; Li S; Zhang M; Yu L; Feng T; Zhang X; Wu X; Wu JZ; Chen L
J Med Chem; 2014 Oct; 57(19):8026-34. PubMed ID: 25238284
[TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase inhibitor suberoylanilide hydroxamic acid alleviates liver fibrosis by suppressing the transforming growth factor-β1 signal pathway.
Wang Y; Zhao L; Jiao FZ; Zhang WB; Chen Q; Gong ZJ
Hepatobiliary Pancreat Dis Int; 2018 Oct; 17(5):423-429. PubMed ID: 30249543
[TBL] [Abstract][Full Text] [Related]
9. Blocking the class I histone deacetylase ameliorates renal fibrosis and inhibits renal fibroblast activation via modulating TGF-beta and EGFR signaling.
Liu N; He S; Ma L; Ponnusamy M; Tang J; Tolbert E; Bayliss G; Zhao TC; Yan H; Zhuang S
PLoS One; 2013; 8(1):e54001. PubMed ID: 23342059
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis.
Korfei M; Stelmaszek D; MacKenzie B; Skwarna S; Chillappagari S; Bach AC; Ruppert C; Saito S; Mahavadi P; Klepetko W; Fink L; Seeger W; Lasky JA; Pullamsetti SS; Krämer OH; Guenther A
PLoS One; 2018; 13(11):e0207915. PubMed ID: 30481203
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase inhibition promotes fibroblast apoptosis and ameliorates pulmonary fibrosis in mice.
Sanders YY; Hagood JS; Liu H; Zhang W; Ambalavanan N; Thannickal VJ
Eur Respir J; 2014 May; 43(5):1448-58. PubMed ID: 24603818
[TBL] [Abstract][Full Text] [Related]
12. Discovery of novel potential selective HDAC8 inhibitors by combine ligand-based, structure-based virtual screening and in-vitro biological evaluation.
Debnath S; Debnath T; Bhaumik S; Majumdar S; Kalle AM; Aparna V
Sci Rep; 2019 Nov; 9(1):17174. PubMed ID: 31748509
[TBL] [Abstract][Full Text] [Related]
13. Computer-aided identification of new histone deacetylase 6 selective inhibitor with anti-sepsis activity.
Yoo J; Kim SJ; Son D; Seo H; Baek SY; Maeng CY; Lee C; Kim IS; Jung YH; Lee SM; Park HJ
Eur J Med Chem; 2016 Jun; 116():126-135. PubMed ID: 27060764
[TBL] [Abstract][Full Text] [Related]
14. Investigating the potential effects of selective histone deacetylase 6 inhibitor ACY1215 on infarct size in rats with cardiac ischemia-reperfusion injury.
Lin CF; Hsu KC; HuangFu WC; Lin TE; Huang HL; Pan SL
BMC Pharmacol Toxicol; 2020 Mar; 21(1):21. PubMed ID: 32178737
[TBL] [Abstract][Full Text] [Related]
15. Harnessing the Role of HDAC6 in Idiopathic Pulmonary Fibrosis: Design, Synthesis, Structural Analysis, and Biological Evaluation of Potent Inhibitors.
Campiani G; Cavella C; Osko JD; Brindisi M; Relitti N; Brogi S; Saraswati AP; Federico S; Chemi G; Maramai S; Carullo G; Jaeger B; Carleo A; Benedetti R; Sarno F; Lamponi S; Rottoli P; Bargagli E; Bertucci C; Tedesco D; Herp D; Senger J; Ruberti G; Saccoccia F; Saponara S; Gorelli B; Valoti M; Kennedy B; Sundaramurthi H; Butini S; Jung M; Roach KM; Altucci L; Bradding P; Christianson DW; Gemma S; Prasse A
J Med Chem; 2021 Jul; 64(14):9960-9988. PubMed ID: 34251197
[TBL] [Abstract][Full Text] [Related]
16. A Therapeutic Perspective of HDAC8 in Different Diseases: An Overview of Selective Inhibitors.
Fontana A; Cursaro I; Carullo G; Gemma S; Butini S; Campiani G
Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077415
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase: a potential therapeutic target for fibrotic disorders.
Pang M; Zhuang S
J Pharmacol Exp Ther; 2010 Nov; 335(2):266-72. PubMed ID: 20719940
[TBL] [Abstract][Full Text] [Related]
18. The histone deacetylase inhibitor, romidepsin, as a potential treatment for pulmonary fibrosis.
Conforti F; Davies ER; Calderwood CJ; Thatcher TH; Jones MG; Smart DE; Mahajan S; Alzetani A; Havelock T; Maher TM; Molyneaux PL; Thorley AJ; Tetley TD; Warner JA; Packham G; Ganesan A; Skipp PJ; Marshall BJ; Richeldi L; Sime PJ; O'Reilly KMA; Davies DE
Oncotarget; 2017 Jul; 8(30):48737-48754. PubMed ID: 28467787
[TBL] [Abstract][Full Text] [Related]
19. Suberoylanilide hydroxamic acid (SAHA) inhibits transforming growth factor-beta 2-induced increases in aqueous humor outflow resistance.
Fujimoto T; Inoue-Mochita M; Iraha S; Tanihara H; Inoue T
J Biol Chem; 2021 Sep; 297(3):101070. PubMed ID: 34389355
[TBL] [Abstract][Full Text] [Related]
20. Targeting Histone Deacetylases in Idiopathic Pulmonary Fibrosis: A Future Therapeutic Option.
Korfei M; Mahavadi P; Guenther A
Cells; 2022 May; 11(10):. PubMed ID: 35626663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]